Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ovid Therapeutics (OVID) stock

Learn how to easily invest in Ovid Therapeutics stock.

Ovid Therapeutics Inc
NASDAQ: OVID - USD
BIOTECHNOLOGY
$3.71
-$0.03 (-0.80%)

Ovid Therapeutics Inc is a biotechnology business based in the US. Ovid Therapeutics shares (OVID) are listed on the NASDAQ and all prices are listed in US Dollars. Ovid Therapeutics employs 64 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Ovid Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OVID – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ovid Therapeutics stock price (NASDAQ: OVID)

Use our graph to track the performance of OVID stocks over time.

Ovid Therapeutics shares at a glance

Information last updated 2021-07-22.
Latest market close$4.15
52-week range$2.25 - $8.37
50-day moving average $4.13
200-day moving average $3.66
Wall St. target price$4.88
PE ratio 2.1791
Dividend yield N/A (0%)
Earnings per share (TTM) $1.75

Buy Ovid Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ovid Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ovid Therapeutics price performance over time

Historical closes compared with the close of $4.15 from 2021-05-28

1 week (2021-07-16) N/A
1 month (2021-06-25) -4.38%
3 months (2021-04-27) 8.07%
6 months (2021-01-23) N/A
1 year (2020-07-23) N/A
2 years (2019-07-23) N/A
3 years (2018-07-23) N/A
5 years (2016-07-23) N/A

Is Ovid Therapeutics under- or over-valued?

Valuing Ovid Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ovid Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ovid Therapeutics's P/E ratio

Ovid Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Ovid Therapeutics shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Ovid Therapeutics's EBITDA

Ovid Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $115.7 million.

The EBITDA is a measure of a Ovid Therapeutics's overall financial performance and is widely used to measure a its profitability.

Ovid Therapeutics financials

Revenue TTM $221 million
Operating margin TTM 52.23%
Gross profit TTM $-48,020,415
Return on assets TTM 48.22%
Return on equity TTM 84.39%
Profit margin 52.04%
Book value $3.26
Market capitalisation $259 million

TTM: trailing 12 months

Shorting Ovid Therapeutics shares

There are currently 1.7 million Ovid Therapeutics shares held short by investors – that's known as Ovid Therapeutics's "short interest". This figure is 52.5% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Ovid Therapeutics shares can be evaluated.

Ovid Therapeutics's "short interest ratio" (SIR)

Ovid Therapeutics's "short interest ratio" (SIR) is the quantity of Ovid Therapeutics shares currently shorted divided by the average quantity of Ovid Therapeutics shares traded daily (recently around 1.1 million). Ovid Therapeutics's SIR currently stands at 1.59. In other words for every 100,000 Ovid Therapeutics shares traded daily on the market, roughly 1590 shares are currently held short.

However Ovid Therapeutics's short interest can also be evaluated against the total number of Ovid Therapeutics shares, or, against the total number of tradable Ovid Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ovid Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Ovid Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0517% of the tradable shares (for every 100,000 tradable Ovid Therapeutics shares, roughly 52 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ovid Therapeutics.

Find out more about how you can short Ovid Therapeutics stock.

Ovid Therapeutics share dividends

We're not expecting Ovid Therapeutics to pay a dividend over the next 12 months.

Ovid Therapeutics share price volatility

Over the last 12 months, Ovid Therapeutics's shares have ranged in value from as little as $2.25 up to $8.37. A popular way to gauge a stock's volatility is its "beta".

OVID.US volatility(beta: 1.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ovid Therapeutics's is 1.7968. This would suggest that Ovid Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ovid Therapeutics overview

Ovid Therapeutics Inc. , a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H.

Stocks similar to Ovid Therapeutics

Frequently asked questions

What percentage of Ovid Therapeutics is owned by insiders or institutions?
Currently 29.174% of Ovid Therapeutics shares are held by insiders and 55.629% by institutions.
How many people work for Ovid Therapeutics?
Latest data suggests 64 work at Ovid Therapeutics.
When does the fiscal year end for Ovid Therapeutics?
Ovid Therapeutics's fiscal year ends in December.
Where is Ovid Therapeutics based?
Ovid Therapeutics's address is: 1460 Broadway, New York, NY, United States, 10036
What is Ovid Therapeutics's ISIN number?
Ovid Therapeutics's international securities identification number is: US6904691010
What is Ovid Therapeutics's CUSIP number?
Ovid Therapeutics's Committee on Uniform Securities Identification Procedures number is: 690469101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site